Measure #176: Rheumatoid Arthritis (RA): Tuberculosis Screening – National Quality Strategy
Domain: Effective Clinical Care

2017 OPTIONS FOR INDIVIDUAL MEASURES:
REGISTRY ONLY

MEASURE TYPE:
Process

DESCRIPTION:
Percentage of patients aged 18 years and older with a diagnosis of rheumatoid arthritis (RA) who have documentation of a tuberculosis (TB) screening performed and results interpreted within 6 months prior to receiving a first course of therapy using a biologic disease-modifying anti-rheumatic drug (DMARD)

INSTRUCTIONS:
This measure is to be reported a minimum of once per performance period for patients with a diagnosis of RA who are being considered or prescribed a first course of biologic disease-modifying anti-rheumatic drug therapy seen during the performance period. This measure may be reported by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

Measure Reporting:
The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

DENOMINATOR:
All patients aged 18 years and older with a diagnosis of RA who are receiving a first course of therapy using a biologic DMARD

Denominator Instructions: Patients are considered to be receiving a first course of therapy using a biologic DMARD only if they have never previously been prescribed or dispensed a biologic DMARD.

Denominator Criteria (Eligible Cases):
Patients aged ≥ 18 years on date of encounter
AND
Diagnosis for rheumatoid arthritis (RA) (ICD-10-CM): M05.00, M05.011, M05.012, M05.019, M05.021, M05.022, M05.029, M05.031, M05.032, M05.039, M05.041, M05.042, M05.049, M05.051, M05.052, M05.059, M05.061, M05.062, M05.069, M05.071, M05.072, M05.079, M05.09, M05.111, M05.112, M05.119, M05.121, M05.122, M05.129, M05.131, M05.132, M05.139, M05.141, M05.142, M05.149, M05.151, M05.152, M05.159, M05.161, M05.162, M05.169, M05.171, M05.172, M05.179, M05.19, M05.20, M05.211, M05.212, M05.219, M05.221, M05.222, M05.229, M05.231, M05.232, M05.239, M05.241, M05.242, M05.249, M05.251, M05.252, M05.259, M05.261, M05.262, M05.269, M05.271, M05.272, M05.279, M05.30, M05.311, M05.312, M05.319, M05.321, M05.322, M05.329, M05.331, M05.332, M05.339, M05.341, M05.342, M05.349, M05.351, M05.352, M05.359, M05.361, M05.362, M05.369, M05.371, M05.372, M05.379, M05.39, M05.40, M05.411, M05.412, M05.419, M05.421, M05.422, M05.429, M05.431, M05.432, M05.439, M05.441, M05.442, M05.449, M05.451, M05.452, M05.459, M05.461, M05.462, M05.469, M05.471, M05.472, M05.479, M05.49, M05.50, M05.511, M05.512, M05.519, M05.521, M05.522, M05.529, M05.531, M05.532, M05.539, M05.541, M05.542, M05.549, M05.551, M05.552, M05.559, M05.561, M05.562, M05.569, M05.571, M05.572, M05.579, M05.59, M05.60, M05.611, M05.612, M05.619, M05.621, M05.622, M05.629, M05.631, M05.632, M05.639, M05.641, M05.642, M05.649,
M05.651, M05.652, M05.659, M05.661, M05.662, M05.669, M05.671, M05.672, M05.679, M05.69, M05.70, M05.711, M05.712, M05.719, M05.721, M05.722, M05.729, M05.731, M05.732, M05.739, M05.741, M05.742, M05.749, M05.751, M05.752, M05.759, M05.761, M05.762, M05.769, M05.771, M05.772, M05.779, M05.79, M05.80, M05.811, M05.812, M05.819, M05.821, M05.822, M05.829, M05.831, M05.832, M05.839, M05.841, M05.842, M05.849, M05.851, M05.852, M05.859, M05.861, M05.862, M05.869, M05.871, M05.872, M05.879, M05.89, M06.00, M06.011, M06.012, M06.019, G0402

AND

Patient encounter during the performance period (CPT or HCPCS): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, G0402

WITHOUT

Telehealth Modifier: GQ, GT

AND

Patient receiving first-time biologic disease modifying anti-rheumatic drug therapy for rheumatoid arthritis: 4195F

NUMERATOR:

Patients for whom a TB screening was performed and results interpreted within 6 months prior to receiving a first course of therapy using a biologic DMARD

Definition:

Biologic DMARD Therapy – Includes Adalimumab, Etanercept, Infliximab, Abatacept, Anakinra, Rituximab, Certolizumab pegol (Cimzia), Tocilizumab, Golimumab (Simponi), Humira, Enbrel, Ocrelizumab, Remicade, Rituxan, Actemra, Kineret, Xeljanz, Tofacitinib, Belimumab, Benlysta

Numerator Options:

Performance Met: TB screening performed and results interpreted within six months prior to initiation of first-time biologic disease modifying anti-rheumatic drug therapy for RA (3455F)

OR

Denominator Exception: Documentation of medical reason for not screening for TB or interpreting results (ie, patient positive for TB and documentation of past treatment; patient who has recently completed a course of anti-TB therapy) (3455F with 1P)

OR

Performance Not Met: TB screening not performed or results not interpreted, reason not otherwise specified (3455F with 8P)

RATIONALE:

Before initiating biologic DMARDs for a patient with RA, it is essential to screen the patient for tuberculosis, as research has documented a higher incidence of TB after anti-TNFα therapy. All patients being considered for biologic DMARD should receive a tuberculin skin test, even if the patient has previously received the BCG vaccination. Test results, in addition to patient risk for TB and other tests, should be used to assess the patient’s risk for latent TB infection. This is a patient safety measure.
CLINICAL RECOMMENDATION STATEMENTS:
The American College of Rheumatology recommends screening to identify latent TB infection (LTBI) in all RA patients being considered for therapy with biologic agents, regardless of the presence of risk factors for LTBI. (Level of Evidence: C) (ACR, 2012)

COPYRIGHT:
The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.

Commercial uses of the Measures require a license agreement between the user and the American Medical Association (AMA), [on behalf of the Physician Consortium for Performance Improvement® (PCPI®)] or American College of Rheumatology (ACR). Neither the AMA, ACR, PCPI, nor its members shall be responsible for any use of the Measures.

The AMA’s, PCPI’s and National Committee for Quality Assurance’s significant past efforts and contributions to the development and updating of the Measures is acknowledged. ACR is solely responsible for the review and enhancement (“Maintenance”) of the Measures as of July 25, 2014.

ACR encourages use of the Measures by other health care professionals, where appropriate.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

© 2014 American Medical Association and American College of Rheumatology. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, ACR, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

2017 Registry Individual Measure Flow

#176: Rheumatoid Arthritis (RA): Tuberculosis Screening

Start

Denominator

Patient Age at Date of Encounter ≥ 18 Years

Yes

No

Diagnosis for RA as Listed in Denominator*

No

Encounter as Listed in Denominator* (1/1/2017 thru 12/31/2017)

Yes

No

Telehealth Modifier: GO, GT

Yes

No

Patient Receiving First-Time Biologic Disease Modifying Anti-Rheumatic Drug Therapy for RA 4195F or equivalent

Yes

No

Numerator

TB Screening Performed and Results Interpreted Within Six Months Prior to Initiation of First-Time Biologic Disease Modifying Anti-Rheumatic Drug Therapy for RA

Yes

No

Documentation of Medical Reason for Not Screening for TB or Interpreting Results (ie, Patient Positive for TB and Documentation of Past Treatment; Patient who has Recently Completed a Course of Anti-TB Therapy)

Yes

No

TB Screening Not Performed or Results Not Interpreted, Reason Not Specified

Yes

No

Data Completeness Met + Performance Met 3455F or equivalent (4 patients)

Data Completeness Met + Denominator Exception 3455F-1P or equivalent (1 patient)

Data Completeness Met + Performance Not Met 3455F-SP or equivalent (2 patients)

Include in Eligible Population/ Denominator (8 patients)

*See the posted Measure Specification for specific coding and instructions to report this measure.

NOTE: Reporting Frequency: Patient-process

CPT only copyright 2016 American Medical Association. All rights reserved.

The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.
2017 Registry Individual Measure Flow
#176: Rheumatoid Arthritis (RA): Tuberculosis Screening

SAMPLE CALCULATIONS:

Data Completeness=
Performance Met (a=4 patients) + Denominator Exception (b=1 patient) + Performance Not Met (c=2 patients) = 7 patients = 87.50%
Eligible Population / Denominator (d=8 patients) = 8 patients

Performance Rate=
Performance Met (a=4 patients) = 4 patients = 66.67%
Data Completeness Numerator (7 patients) – Denominator Exception (b=1 patient) = 6 patients
2017 Registry Individual Measure Flow
#176: Rheumatoid Arthritis (RA): Tuberculosis Screening

Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in reporting this Individual Measure.

1. Start with Denominator

2. Check Patient Age:
   a. If the Age is greater than or equal to 18 years of age at Date of Service and equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing.
   b. If the Age is greater than or equal to 18 years of age at Date of Service and equals Yes during the measurement period, proceed to check Patient Diagnosis.

3. Check Patient Diagnosis:
   a. If Diagnosis of RA as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Diagnosis of RA as Listed in the Denominator equals Yes, proceed to check Encounter Performed.

4. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, include in the Eligible Population.

5. Check Telehealth Modifier:
   a. If Telehealth Modifier as Listed in the Denominator equals Yes, do not include in Eligible Patient Population. Stop Processing.
   b. If Telehealth Modifier as Listed in the Denominator equals No, include in the Eligible Population.

6. Check Patient Receiving First-Time Biologic Disease Modifying Anti-Rheumatic Drug Therapy for RA:
   a. If Patient Receiving First-Time Biologic Disease Modifying Anti-Rheumatic Drug Therapy for RA as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Patient Receiving First-Time Biologic Disease Modifying Anti-Rheumatic Drug Therapy for RA as Listed in the Denominator equals Yes, include in the Eligible Population.

7. Denominator Population:
   a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 8 episodes in the sample calculation.

8. Start Numerator

9. Check TB Screening Performed and Results Interpreted Within Six Months Prior to Initiation of First-Time Biologic Disease Modifying Anti-Rheumatic Drug Therapy for RA:
a. If TB Screening Performed and Results Interpreted Within Six Months Prior to Initiation of First-Time Biologic Disease Modifying Anti-Rheumatic Drug Therapy for RA equals Yes, include in Data Completeness Met and Performance Met.

b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 4 episodes in Sample Calculation.

c. If TB Screening Performed and Results Interpreted Within Six Months Prior to Initiation of First-Time Biologic Disease Modifying Anti-Rheumatic Drug Therapy for RA equals No, proceed to Documentation of Medical Reason for Not Screening for TB or Interpreting Results (ie, Patient Positive for TB and Documentation of Past Treatment; Patient who has Recently Completed a Course of Anti-TB Therapy).

10. Check Documentation of Medical Reason for Not Screening for TB or Interpreting Results (ie, Patient Positive for TB and Documentation of Past Treatment; Patient who has Recently Completed a Course of Anti-TB Therapy):

a. If Documentation of Medical Reason for Not Screening for TB or Interpreting Results (ie, Patient Positive for TB and Documentation of Past Treatment; Patient who has Recently Completed a Course of Anti-TB Therapy) equals Yes, include in Data Completeness Met and Performance Exception.

b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b equals 1 episode in the Sample Calculation.

c. If Documentation of Medical Reason for Not Screening for TB or Interpreting Results (ie, Patient Positive for TB and Documentation of Past Treatment; Patient who has Recently Completed a Course of Anti-TB Therapy) equals No, proceed to TB Screening Not Performed or Results Not Interpreted, Reason Not Specified.

11. Check TB Screening Not Performed or Results Not Interpreted, Reason Not Specified:

a. If TB Screening Not Performed or Results Not Interpreted, Reason Not Specified equals Yes, include in Data Completeness Met and Performance Not Met.

b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter c equals 2 episodes in the Sample Calculation.

c. If TB Screening Not Performed or Results Not Interpreted, Reason Not Specified equals No, proceed to Data Completeness Not Met.

12. Check Data Completeness Not Met:

a. If Data Completeness Not Met equals No, Quality Data Code or equivalent not reported. 1 episode has been subtracted from the data completeness numerator in the sample calculation.

---

**SAMPLE CALCULATIONS:**

\[
\text{Performance Rate} = \frac{\text{Performance Met (a=4 patients)}}{\text{Eligible Population / Denominator (d=8 patients)}} = \frac{4}{8} = 66.67\% \\
\text{Data Completeness Numerator (7 patients) } - \text{ Denominator Exception (b=1 patient) } = 6 \text{ patients}
\]

\[
\text{Data Completeness}= \frac{\text{Performance Met (a=4 patients) } + \text{Denominator Exception (b=1 patient) } + \text{Performance Not Met (c=2 patients) } }{7 \text{ patients}} = \frac{7}{8} = 87.50\%
\]